Analysts project Intellia Therapeutics will report Q2 2026 revenue of $13.4 million and a net loss of $0.80 per share, with the current stock price of $10.68 trading significantly below the average analyst target of $20.19. The single most important story for this earnings report is the progress of the rolling Biologics License Application for lonvo-z, the company’s gene-editing therapy for hereditary angioedema.
This follows the announcement of positive topline data from the pivotal HAELO Phase 3 trial and the initiation of the regulatory submission process earlier this year. Furthermore, investors are monitoring the advancement of the Phase 3 MAGNITUDE program for nex-z, supported by a fortified balance sheet that extends the company's operational runway into 2028.